Show simple item record

dc.contributor.authorAnderson, Paul S.
dc.description.abstractIntravenous ascorbic acid (IVAA) is a well-known intervention in medicine, which currently is rarely used in US hospitals. Due to the unusual and extreme clinical demands of hospitalized COVID-19 patients, IVAA has been implemented in Chinese hospitals, and data published by the “Expert Group on Clinical Treatment of New Corona Virus Disease in Shanghai” (direct translation) details the use of IVAA as safe and effective adjunctive care of hospitalized COVID-19 patients. In the IVAA treated group, there was no mortality, no reported side effects, and shorter hospital stays universally. In addition, the Shanghai Expert Group recommends IVAA use in extremely critical settings within COVID-19 patients. IVAA, as an intervention, is relatively inexpensive and simple for both pharmacy and nursing staff use. The primary author has also used IVAA in the US under a NIH funded human trial and has extensive subject matter knowledge and expertise.en_US
dc.subjectAscorbic Aciden_US
dc.titleIntravenous Ascorbic Acid (IVAA) for COVID-19: supportive treatment in hospitalized COVID-19 patients: based on use in China and US settingsen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typeOther publicationsen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record